XORTX Therapeutics Inc. (XRTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

XORTX Therapeutics Inc. (XRTX) closed at USD 1.56 on 2026-10-14, a change of -50.6 % over the past year, with a market capitalization of USD 2.58M.

XORTX Therapeutics Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

XORTX Therapeutics Inc. key figures

Previous close

USD 1.56 (2026-10-14)

1-year change

-50.6 %

Market cap

USD 2.58M

Enterprise value

USD 1.59M

P/E ratio (trailing)

-0.63

P/E ratio (forward)

1.77

EPS (trailing)

-2.27

EPS (forward)

0.80

PEG ratio

n/a

Price to book

0.45

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.10

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for XORTX Therapeutics Inc. and compare it with other stocks.